Correction to: Bone Marrow Transplant https://doi.org/10.1038/s41409-021-01475-8, published online 28 September 2021
In this article the statement in the Funding information section was incorrectly given as
“This work was partially supported by the National Institutes of Health Grant UL1-TR003142 and Grant P30-CA124435.” and should have read
“This manuscript is partially supported by the Biostatistics Shared Resource (BSR) of the NIH-funded Stanford Cancer Institute: P30CA124435.”
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1038/s41409-021-01475-8.
Rights and permissions
About this article
Cite this article
Liang, E.C., Chen, C., Lu, R. et al. Correction to: Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 57, 694 (2022). https://doi.org/10.1038/s41409-022-01606-9
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41409-022-01606-9
